These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 25275047)
1. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma. Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047 [TBL] [Abstract][Full Text] [Related]
2. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543 [TBL] [Abstract][Full Text] [Related]
3. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251 [TBL] [Abstract][Full Text] [Related]
4. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469 [TBL] [Abstract][Full Text] [Related]
5. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547 [TBL] [Abstract][Full Text] [Related]
6. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430 [TBL] [Abstract][Full Text] [Related]
7. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637 [TBL] [Abstract][Full Text] [Related]
9. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841 [No Abstract] [Full Text] [Related]
10. Characterization of DLBCL with a PMBL gene expression signature. Duns G; Viganò E; Ennishi D; Sarkozy C; Hung SS; Chavez E; Takata K; Rushton C; Jiang A; Ben-Neriah S; Woolcock BW; Slack GW; Hsi ED; Craig JW; Hilton LK; Shah SP; Farinha P; Mottok A; Gascoyne RD; Morin RD; Savage KJ; Scott DW; Steidl C Blood; 2021 Jul; 138(2):136-148. PubMed ID: 33684939 [TBL] [Abstract][Full Text] [Related]
11. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955 [TBL] [Abstract][Full Text] [Related]
12. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593 [TBL] [Abstract][Full Text] [Related]
14. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470 [TBL] [Abstract][Full Text] [Related]
15. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Choi JW; Kim Y; Lee JH; Kim YS Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077 [TBL] [Abstract][Full Text] [Related]
16. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466 [TBL] [Abstract][Full Text] [Related]
17. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations. Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383 [TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression. Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548 [TBL] [Abstract][Full Text] [Related]
19. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. Yuan J; Wright G; Rosenwald A; Steidl C; Gascoyne RD; Connors JM; Mottok A; Weisenburger DD; Greiner TC; Fu K; Smith L; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Ott G; Vose JM; Staudt LM; Chan WC; Am J Surg Pathol; 2015 Oct; 39(10):1322-30. PubMed ID: 26135560 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly. Gebauer N; Gebauer J; Hardel TT; Bernard V; Biersack H; Lehnert H; Rades D; Feller AC; Thorns C Leuk Lymphoma; 2015 Apr; 56(4):1100-6. PubMed ID: 25030036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]